TGF-beta1: a novel target for cardiovascular pharmacology.
Transforming growth factor beta-1 (TGF-beta1) plays a key role in cardiovascular disease by a process which allows the loss of its protective properties. The first therapeutic attempt to restore its function by selectively designed novel drugs are being made. In addition, it has been recognized that the TGF-beta1 pathway is involved in the vascular mechanism of action of some current clinical drugs, such as acetylsalicylic acid, thiazolidinediones and statins. The aim of this paper is to review the possible value of TGF-beta1 as both a disease marker and a therapeutical target for cardiovascular disease.
Redondo
Santiago
S
Department of Pharmacology, School of Medicine, Universidad Complutense de Madrid Av Complutense s/n, Madrid, Spain.
Santos-Gallego
Carlos G
CG
Tejerina
Teresa
T
D000818:Animals; D050197:Atherosclerosis / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000378:metabolism; D002319:Cardiovascular System / Q000378:metabolism*; D002450:Cell Communication; D003251:Constriction, Pathologic / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000378:metabolism; D008954:Models, Biological; D015398:Signal Transduction; D053773:Transforming Growth Factor beta1 / Q000378:metabolism / Q000502:physiology*
D016207:Cytokines; D036341:Intercellular Signaling Peptides and Proteins; D053773:Transforming Growth Factor beta1